-
公开(公告)号：US07964725B2
公开(公告)日：2011-06-21
申请号：US12644249
申请日：2009-12-22
IPC分类号： C07D241/08
CPC分类号： C07D403/12 , C07D241/24 , C07D401/12
摘要： The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, R2, R3, n, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).
摘要翻译： 本发明涉及一组新的式（I）化合物或其盐：其中R1，R2，R3，n，A和HET-1如说明书中所述，其可用于治疗或预防 通过葡萄糖激酶（GLK）如2型糖尿病介导的疾病或医学病症。 本发明还涉及包含所述化合物的药物组合物，使用所述化合物治疗由GLK介导的疾病的方法和制备式（I）化合物的方法。
-
公开(公告)号：US07671060B2
公开(公告)日：2010-03-02
申请号：US11924888
申请日：2007-10-26
IPC分类号： A61K31/4965
CPC分类号： C07D403/12 , C07D241/24 , C07D401/12
摘要： The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, R2, R3, n, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).
摘要翻译： 本发明涉及一组新的式（I）化合物或其盐：其中R1，R2，R3，n，A和HET-1如说明书中所述，其可用于治疗或预防 通过葡萄糖激酶（GLK）如2型糖尿病介导的疾病或医学病症。 本发明还涉及包含所述化合物的药物组合物，使用所述化合物治疗由GLK介导的疾病的方法和制备式（I）化合物的方法。
-
公开(公告)号：US20080318968A1
公开(公告)日：2008-12-25
申请号：US11924888
申请日：2007-10-26
IPC分类号： A61K31/497 , C07D403/12 , A61P3/10 , C07D401/12 , A61K31/4439
CPC分类号： C07D403/12 , C07D241/24 , C07D401/12
摘要： The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, R2, R3, n, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).
摘要翻译： 本发明涉及一组新的式（I）化合物或其盐：其中R1，R2，R3，n，A和HET-1如说明书中所述，其可用于治疗或预防 通过葡萄糖激酶（GLK）如2型糖尿病介导的疾病或医学病症。 本发明还涉及包含所述化合物的药物组合物，使用所述化合物治疗由GLK介导的疾病的方法和制备式（I）化合物的方法。
-
公开(公告)号：US20100173825A1
公开(公告)日：2010-07-08
申请号：US12644249
申请日：2009-12-22
IPC分类号： A61K31/497 , A61P3/10 , A61P3/04 , A61K38/28
CPC分类号： C07D403/12 , C07D241/24 , C07D401/12
摘要： The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, R2, R3, n, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).
摘要翻译： 本发明涉及一组新的式（I）化合物或其盐：其中R1，R2，R3，n，A和HET-1如说明书中所述，其可用于治疗或预防 通过葡萄糖激酶（GLK）如2型糖尿病介导的疾病或医学病症。 本发明还涉及包含所述化合物的药物组合物，使用所述化合物治疗由GLK介导的疾病的方法和制备式（I）化合物的方法。
-
-
-
搜索结果
4 条记录 (耗时 0.023 秒)
